ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - location/WA/6000-Perth-Royal-Perth-Hospital
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
27
trial(s) found.
NCT07710885
Advanced
Phase 3
Recruiting
A Phase 3, Randomized-Controlled, Open-Label, Multi-Regional, International Study of Futibatinib (TAS-120) and Zimberelimab (AB122) in Combination With Gemcitabine Plus Cisplatin Versus Durvalumab or Pembrolizumab in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers (
FOENIX-BTC
)
anti-PD-1 monoclonal antibody
anti-PD-L1 monoclonal antibody
antimetabolite
pan-FGFR inhibitor,irreversible
platinum-based antineoplastic agent
Biliary tract cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT07651618
Advanced
Phase 2
Not yet recruiting
PERTIL-01
: A Phase II Trial of Tumour Infiltrating Lymphocyte Adoptive Cell Therapy in Patients With Immune Checkpoint Inhibitor Resistant Unresectable or Metastatic Melanoma
Aldesleukin
Cyclophosphamide
Fludarabine
IL-2 variant
alkylating agent
antimetabolite
cancer therapy
cancer therapy,IL-2-targeting
cytokine therapy
cytokine therapy,IL-2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,IL-2-targeting
Melanoma
Skin cancer
WA
6000 - Perth - Royal Perth Hospital
NCT07623200
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Open-Label Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia and a CALR Mutation Previously Treated With Cytoreductive Therapy (
EXCALIBUR-ET2
)
anti-CALR monoclonal antibody
Essential thrombocythaemia
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT07509151
Haem
Phase 3
Recruiting
A Phase III, Randomised, Open-label, Multicentre, Study of Surovatamig as Consolidation Therapy Versus Observation After First-line Induction Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV (
SOUNDTRACK-C1
)
bispecific T-cell engager,CD19-targeting
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6168 - Cooloongup - Rockingham Hospital
NCT07211958
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Newly Diagnosed AML With an NPM1 Mutation (
REVEAL-ND-NPM1
)
menin-MLL1 inhibitor
placebo
Acute myeloid leukaemia
NSW
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Linear Clinical Research
NCT07155226
Haem
Phase 1 / Phase 2
Recruiting
A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression (
MOMENTUM
)
menin-MLL1 inhibitor
Acute lymphoblastic leukaemia
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6000 - Perth - Royal Perth Hospital
NCT06824168
Haem
Phase 2
Recruiting
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission (
AC220-167
)
FLT3 inhibitor
KIT inhibitor
Acute myeloid leukaemia
Leukaemia
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
NCT06717347
Haem
Phase 3
Recruiting
A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010) (
2140-010
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3066 - Epping - Northern Hospital
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4812 - Townsville - Townsville University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06656494
Haem
Phase 1
Recruiting
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies. (
ICP-CL-01205
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Leukaemia
Myelodysplastic syndrome
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT06479135
Haem
Phase 3
Recruiting
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Na\xEFve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib (
POIESIS
)
JAK1/JAK2 inhibitor
MDM2 inhibitor
placebo
Myelofibrosis
NSW
2217 - Kogarah - St George Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT06428019
Haem
Phase 3
Recruiting
A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination With Obinutuzumab or Acalabrutinib With Different Ramp- Up Periods in Previously Untreated Subjects With CLL (
M24-287
)
BTK inhibitor
Bcl2 inhibitor
anti-CD20 monoclonal antibody
Chronic lymphocytic leukaemia
Small lymphocytic lymphoma
NSW
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
QLD
4812 - Townsville - Townsville University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT06372717
Haem
Phase 1
Recruiting
A Phase 1 Study to Assess the Safety and Antitumor Activity of APL-4098 Alone and in Combination With Azacitidine and in Combination With Azacitidine Plus Venetoclax in Adults With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome/AML (MDS/AML) or Myelodysplastic Syndrome With Excess Blasts (MDS-EB) (
AP30CP01
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
multikinase inhibitor,integrated stress response-targeting
Acute myeloid leukaemia
Myelodysplastic syndrome
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Hollywood Private Hospital
NCT06163430
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (
CARDINAL
)
BCR-ABL1 inhibitor,allosteric
Chronic myelogenous leukaemia
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT06051409
Haem
Phase 3
Recruiting
A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investigator's Choice of TKI Combined With Chemotherapy in Patients With Newly Diagnosed Ph+ ALL (
HQP1351AG301
)
BCR-ABL1 inhibitor,third generation
Leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NCT05866458
Curative
Recruiting
Radiation OmisSion in PAtients With CLinically Node Negative Breast Cancer Undergoing Lumpectomy and With a PathologIc Complete REsponse After Neoadjuvant Chemotherapy (
ROSALIE
)
Breast cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2060 - North Sydney - Mater Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2487 - Cudgen - Tweed Valley Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3002 - East Melbourne - Victoria Breast & Oncology Care
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3165 - Bentleigh East - Monash Medical Centre - Moorabbin
3844 - Traralgon - Latrobe Regional Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05826535
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of Rondecabtagene Autoleucel, a CD19/CD20 Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy in Participants With Aggressive B-Cell Non-Hodgkin Lymphoma (
LYL314-101
)
autologous CAR-T-cell therapy,CD19/CD20-targeting
Diffuse large B-cell lymphoma
Non-Hodgkin's lymphoma
VIC
3004 - Melbourne, Southbank - Alfred Health
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT05139017
Haem
Phase 2 / Phase 3
Recruiting
A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) (
2140-003
)
anti-ROR1 antibody-drug conjugate
Diffuse large B-cell lymphoma
VIC
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
QLD
4812 - Townsville - Townsville University Hospital
WA
6000 - Perth - Royal Perth Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT04973605
Haem
Phase 1 / Phase 2
Recruiting
A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14) (
BGB-11417-105
)
anti-CD38 monoclonal antibody
glucocorticoid
immunomodulatory imide drug
proteasome inhibitor
Multiple myeloma
ACT
2605 - Garran - The Canberra Hospital
NSW
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
WA
6000 - Perth - Royal Perth Hospital
NCT04811560
Paed
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants With Acute Leukemia (
cAMeLot-1
)
KMT2A inhibitor
Leukaemia
VIC
3168 - Clayton - Monash Medical Centre
QLD
4215 - Southport - Gold Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
NCT04581512
Haem
Phase 1 / Phase 2
Recruiting
A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination With Anti-cancer Treatments in Patients With Advanced Malignancies (
EP0042-101
)
FLT3/Aurora inhibitor
Acute myeloid leukaemia
Chronic myelomonocytic leukaemia
Myelodysplastic syndrome
WA
6000 - Perth - Royal Perth Hospital
NCT04332822
Haem
Phase 3
Recruiting
R-MINI-CHOP Versus R-MINI-CHP in Combination With Polatuzumab-vedotin, as Primary Treatment for Patients With Diffuse Large B-cell Lymphoma, ≥80 Years, or Frail ≥75 Years - an Open Label Randomized Nordic Lymphoma Group Phase III Trial (
POLAR-BEAR
)
anti-CD79b antibody-drug conjugate
Diffuse large B-cell lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute
2487 - Cudgen - Tweed Valley Hospital
2640 - Albury - Albury Wodonga Regional Cancer Centre
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
ACT
2605 - Garran - The Canberra Hospital
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3065 - Fitzroy - St Vincent's Hospital Melbourne
3066 - Epping - Northern Hospital
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
WA
6000 - Perth - Royal Perth Hospital
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
ACTRN12625001031459
Haem
Phase 2
Not yet recruiting
Place-of-care manufactured anti-BCMA chimeric antigen receptor (CAR) T-cells (ARI0002h) in patients with relapsed/refractory multiple myeloma.
autologous CAR-T-cell therapy,BCMA-targeting
Multiple myeloma
WA
6000 - Perth - Royal Perth Hospital
ACTRN12625000994482
Haem
Phase 1 / Phase 2
Not yet recruiting
ALLG AMLM28/A2 (ADAPT): Achieving Durable remissions via Adaptive Pro-survival Targeting in acute myeloid leukaemia (AML)) – VEN/AZA/Pelcitoclax. A therapeutic arm of the ALLG AMLM28 ADAPT Study-Master Protocol. (
ADAPT-A2
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
ACTRN12623000900617
Haem
Phase 2
Recruiting
AMLM28 Platform Study (Master Protocol) - Achieving Durable remissions via Adaptive Pro-survival Targeting in Acute Myeloid Leukaemia (AML) patients receiving Venetoclax and Azacitidine (VEN-AZA) as frontline therapy (
ALLG
)
Bcl2 inhibitor
DNA methyltransferase inhibitor
antimetabolite
Acute myeloid leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
ACT
2605 - Garran - The Canberra Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4575 - Birtinya - Sunshine Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
Warning
: preg_match(): Compilation failed: missing closing parenthesis at offset 43 in
/home/topowadl/articanz.org/table.php
on line
440
ACTRN12621000223831
Haem
Phase 2
Recruiting
Precision Medicine for Chronic Myelomonocytic Leukaemia in Adults: A phase II Trial Studying the Efficacy of Lenzilumab and High Dose Ascorbate with Azacitidine Based on Molecular Profiling. (
PREACH-M--(PREACH-M
)
DNA methyltransferase inhibitor
anti-GM-CSF monoclonal antibody
antimetabolite
vitamin C drug class
Chronic myelomonocytic leukaemia
NSW
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
ACTRN12619000079145
Haem
Phase 1
Not yet recruiting
A Phase I Study of Autologous CD19 Specific Chimeric Antigen Receptor T-cells for Therapy of Relapsed and Refractory B-cell Leukaemia and Lymphoma (
The-AutoCAR19-Trial
)
autologous CAR-T-cell therapy,CD19-targeting
Acute lymphoblastic leukaemia
Chronic lymphocytic leukaemia
Non-Hodgkin's lymphoma
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology
WA
6000 - Perth - Royal Perth Hospital
ACTRN12607000589482
Advanced
Phase 3
Recruiting
Phase III randomised study of Brivanib Alaninate (BMS-582664) in combination with Cetuximab (Erbitux 'Registered trade mark') versus placebo in combination with Cetuximab (Erbitux 'Registered trade mark') in patients with K-Ras wild type tumours previously treated with combination chemotherapy for metastatic colorectal carcinoma to compare overall survival. (
CO.20
)
FGFR1 inhibitor
VEGFR1/2/3 inhibitor
anti-EGFR monoclonal antibody
placebo
Colorectal adenocarcinoma
NSW
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare
QLD
4999 - Unspecified - Clinical Trial Site QLD
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6000 - Perth - Royal Perth Hospital
NA
NA
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (23)
Not yet recruiting (4)
Recruitment Country and State
WA (27)
VIC (21)
NSW (16)
QLD (16)
SA (11)
ACT (5)
NZ (3)
TAS (2)
Phase
Phase 1 (3)
Phase 1 / Phase 2 (7)
Phase 2 (5)
Phase 2 / Phase 3 (1)
Phase 3 (10)
Trial Type
Haem (22)
Advanced (3)
Curative (1)
Paed (1)
Cancer Therapy Class
Bcl2
26%
DNA methyltransferase
22%
CD20
19%
CD19
11%
KMT2A
11%
FGFR
7%
FGFR1
7%
menin-MLL1
7%
menin
7%
FLT3
7%
ROR1
7%
BCR-ABL1
7%
FGFR1/2/3
4%
FGFR2
4%
FGFR3
4%
FGFR4
4%
PD-1
4%
PD-1/PD-L1
4%
PD-L1
4%
IL-2
4%
CALR
4%
KIT
4%
JAK1
4%
JAK2
4%
MDM2
4%
BTK
4%
ISR
4%
multikinase
4%
DPD
4%
orotate phosphoribosyltransferase
4%
CD38
4%
cereblon
4%
proteasome
4%
AURKA
4%
AURKB
4%
Aurora
4%
CD79b
4%
BCMA
4%
GM-CSF
4%
EGFR
4%
VEGFR1
4%
VEGFR2
4%
VEGFR3
4%
Facility
6000 - Perth - Royal Perth Hospital (27)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (11)
3004 - Melbourne, Southbank - Alfred Health (9)
3000 - Melbourne - Peter MacCallum Cancer Centre (7)
3065 - Fitzroy - St Vincent's Hospital Melbourne (7)
3168 - Clayton - Monash Medical Centre (7)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (6)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (5)
2605 - Garran - The Canberra Hospital (5)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (5)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (5)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (5)
3128 - Box Hill - Box Hill Hospital - Eastern Health (4)
4575 - Birtinya - Sunshine Coast University Hospital (4)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (4)
3066 - Epping - Northern Hospital (4)
NA
2170 - Liverpool - Liverpool Hospital (3)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (3)
4812 - Townsville - Townsville University Hospital (3)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (3)
2031 - Randwick - Prince of Wales Hospital (3)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
4215 - Southport - Gold Coast University Hospital (2)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (2)
7000 - Hobart - Royal Hobart Hospital (2)
2487 - Cudgen - Tweed Valley Hospital (2)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (2)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (1)
6168 - Cooloongup - Rockingham Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
6009 - Nedlands - Linear Clinical Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
2217 - Kogarah - St George Hospital (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6009 - Nedlands - Hollywood Private Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
2060 - North Sydney - Mater Hospital (1)
3002 - East Melbourne - Victoria Breast & Oncology Care (1)
3165 - Bentleigh East - Monash Medical Centre - Moorabbin (1)
3844 - Traralgon - Latrobe Regional Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
2050 - Camperdown - Chris O'Brien Lifehouse (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2444 - Port Macquarie - Mid North Coast Cancer Institute-Port Macquarie Base Hospital (1)
2450 - Coffs Harbour - Coffs Harbour Health Campus - The North Coast Cancer Institute (1)
2640 - Albury - Albury Wodonga Regional Cancer Centre (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3021 - St Albans - Western Health - Sunshine Hospital (1)
3550 - Bendigo - Bendigo Health - Bendigo Cancer Centre (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
5006 - North Adelaide - Calvary North Adelaide Hospital, Adelaide Oncology & Haematology (1)
2999 - Unspecified - Clinical Trial Site NSW - GenesisCare (1)
4999 - Unspecified - Clinical Trial Site QLD (1)
Cancer Type
Cancer
Haematological malignancy
Leukaemia
Myeloid leukaemia
Myeloproliferative neoplasm
B-cell malignancy
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Acute myeloid leukaemia
B-cell lymphoma
Solid tumour
Lymphoid leukaemia
Myelodysplastic syndrome
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Chronic lymphocytic leukaemia
Gastrointestinal cancer
Small lymphocytic lymphoma
Acute lymphoblastic leukaemia
Multiple myeloma
Plasma cell disorder
Chronic myelomonocytic leukaemia
Myelodysplastic/Myeloproliferative disease
Biliary tract cancer
Hepatobiliary cancer
Pancreatobiliary cancer
Upper gastrointestinal cancer
Melanoma
Skin cancer
Essential thrombocythaemia
Myelofibrosis
Chronic leukaemia
Chronic myelogenous leukaemia
Breast cancer
Colorectal adenocarcinoma
Colorectal cancer
Lower gastrointestinal cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy